In the tumor microenvironment, cells often experience low oxygen levels due to rapid proliferation outpacing the development of new blood vessels. HIFs activate the transcription of various genes that promote angiogenesis, metabolic reprogramming, and survival under hypoxic conditions, which collectively support tumor growth and dissemination. By targeting HIF pathways, HIF inhibitors aim to stifle these adaptive mechanisms, thereby inhibiting cancer progression.
